Lymphoma Therapeutics Market to Reach $35.2 Billion, Globally, by 2032 at 8.4% CAGR: Allied Market Research

The global lymphoma therapeutics market is driven by factors such as rise in the prevalence of lymphoma, rise in awareness of lymphoma cancer, and surge in investments in R&D activities by pharmaceutical companies for the development of more target specific lymphoma therapeutics

PORTLAND, Ore., April 27, 2023 /PRNewswire/ — Allied Market Research published a report, titled, “Lymphoma therapeutics Market by Disease Type (Hodgkin Lymphoma and Non-Hodgkin Lymphoma), by Treatment Type (Immune Therapy, Chemotherapy, Targeted Therapy and Radiation Therapy), by Route of Administration (Oral Route and Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2023-2032″. According to the report, the lymphoma therapeutics market is valued at $15,691.45 million in 2022 and is estimated to reach $35,207.45 million by 2032, exhibiting a CAGR of 8.4% from 2023 to 2032.

Request Sample Report: https://www.alliedmarketresearch.com/request-sample/1448

Prime determinants of growth

The global lymphoma therapeutics market is driven by factors such as rise in the prevalence of lymphoma, rise in awareness of lymphoma cancer, and surge in investments in R&D activities by pharmaceutical companies for the development of more target specific lymphoma therapeutics. However, the high cost of available treatment and the stringent regulatory compliance for the approval of lymphoma therapeutics are hampering the market growth. On the contrary, the growing prevalence of non-Hodgkin lymphoma and surge in awareness and concern about the availability of various treatment options for lymphoma are expected to offer remunerative opportunities for expansion of the lymphoma therapeutics market during the forecast period.

Report coverage & details:

Covid-19 Scenario

• The global lymphoma therapeutics market was negatively impacted during the pandemic, owing to delayed diagnosis and treatment and impact on clinical trials.
• However, the market is expected to witness a recovery post-pandemic, owing to rise in prevalence of lymphoma and surge in number of drug approvals to treat lymphoma.

Procure Complete Report (481 Pages PDF with Insights, Charts, Tables, and Figures)
https://www.alliedmarketresearch.com/checkout-final/lymphoma-therapeutics-market

The non-hodgkin lymphoma segment to maintain its leadership status throughout the forecast period

Based on disease type, the non-hodgkin lymphoma segment held the highest market share in 2022, accounting for more than four-fifths of the global lymphoma therapeutics market revenue and is estimated to maintain its leadership status throughout the forecast period. This segment is projected to manifest significant growth with a CAGR of 8.7% from 2023 to 2032, owing to rise in the prevalence of non-hodgkin lymphoma and surge in development of new and more effective drugs by key market players to treat non-hodgkin lymphoma (NHL).

The immune therapy segment to maintain its leadership status throughout the forecast period

Based on treatment type, the immune therapy segment held the highest market share in 2022, accounting for more than two-fifths of the global lymphoma therapeutics market revenue and is estimated to maintain its leadership status throughout the forecast period, owing to advancement in immunology, increase in availability of immune therapies, and rise in number of product approvals across the world. However, the targeted therapy segment is projected to manifest a significant CAGR of 9.4% from 2023 to 2032, owing to rise in prevalence of Hodgkin and non-Hodgkin lymphoma and advantages offered by targeted therapies such as the accuracy of the therapy in the targeting of the cancer cells.

The hospital pharmacies segment to maintain its lead position during the forecast period

Based on distribution channel, the hospital pharmacies segment accounted for the largest share in 2022, contributing to more than two-fifths of the global lymphoma therapeutics market revenue and is estimated to maintain its leadership status throughout the forecast period. This segment is projected to manifest significant growth with a CAGR of 9.0% from 2023 to 2032, owing to the fact that lymphoma therapeutics are mostly dispensed in hospital pharmacies for hospitalized patients. In addition, rise in consumption of lymphoma therapeutics in hospitals acts as the key driver of the segment.

For Purchase Inquiry- https://www.alliedmarketresearch.com/purchase-enquiry/1448

North America to maintain its dominance by 2032

Based on region, North America held the highest market share in terms of revenue in 2022, accounting for around two-fifths of the global lymphoma therapeutics market revenue and is estimated to maintain its leadership status throughout the forecast period. The Lymphoma therapeutics market is mainly driven by rise in prevalence of lymphoma, development in lymphoma therapeutics, including targeted therapies and immunotherapies, and surge in number of new product launches by key market players in this region. However, the Asia-Pacific region is expected to witness the fastest CAGR of 9.1% from 2023 to 2032, owing to rise in prevalence of lymphoma and growing initiative in R&D activities for the development of advanced therapies for the treatment of a wide range of lymphomas.

Leading Market Players: –

• AstraZeneca PLC
• Bayer AG
• Bristol Myers Squibb Co.
• Eli Lily and Company
• F Hoffman La Roche Ltd
• Johnson & Johnson
• Gilead Sciences Inc.
• Seagen Inc.
• Teva Pharmaceutical Industries Ltd.
• Pfizer Inc.

The report provides a detailed analysis of these key players of the global lymphoma therapeutics market. These players have adopted different strategies such as new product launches, collaborations, expansion, joint ventures, agreements, and others to increase their market share and maintain dominant shares in different regions. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario. 

Trending Reports in Healthcare Industry:

Biomarkers Market – Global Opportunity Analysis and Industry Forecast, 2020–2030

Male Infertility Market – Global Opportunity Analysis and Industry Forecast, 2020-2030

Biosimilars Market – Global Opportunity Analysis and Industry Forecast, 2020-2030

Synthetic Biology Market- Global Opportunity Analysis and Industry Forecast, 2020–2030

Medical/Diagnostic Imaging Market – Global Opportunity Analysis and Industry Forecast, 2020–2030

Dialysis Market- Global Opportunity Analysis and Industry Forecast, 2020–2030

AVENUE- A Subscription-Based Library (Premium on-demand, subscription-based pricing model) Offered by Allied Market Research:

AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.

Get an access to the library of reports at any time from any device and anywhere. For more details, follow the link: https://www.alliedmarketresearch.com/library-access

“We have also published few syndicated market studies in the similar area that might be of your interest. Below are the report title for your reference, considering Impact of Covid-19 Over This Market which will help you to assess aftereffects of pandemic on short-term and long-term growth trends of this market.”

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220                                                               
United States
Toll Free: +1-800-792-5285                                                             
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
[email protected] 
Web: https://www.alliedmarketresearch.com  
Follow Us on: LinkedIn Twitter

Logo: https://mma.prnewswire.com/media/636519/Allied_Market_Research_Logo.jpg

SOURCE Allied Market Research